News articles about Edwards Lifesciences (NYSE:EW) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edwards Lifesciences earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 45.2227589236603 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Edwards Lifesciences (EW) PT Set at $165.00 by Cowen (americanbankingnews.com)
- Larry L. Wood Sells 6,300 Shares of Edwards Lifesciences Corp (EW) Stock (americanbankingnews.com)
- Edwards Lifesciences Corp (EW) VP Sells $538,992.00 in Stock (americanbankingnews.com)
- FDA clears Edwards Lifesciences hypotension index software – Mass Device (massdevice.com)
- Edwards’ Acumen Hypotension Prediction Index Launches In The U.S. (finance.yahoo.com)
Several analysts recently commented on the company. Cowen set a $165.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $145.00 price target on the stock in a research note on Thursday, February 8th. Guggenheim reaffirmed a “buy” rating and issued a $162.00 price target on shares of Edwards Lifesciences in a research note on Friday, February 2nd. JMP Securities boosted their price target on Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, February 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $155.00 price target on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $141.98.
Edwards Lifesciences (NYSE:EW) traded up $1.94 during trading on Tuesday, reaching $141.34. The company’s stock had a trading volume of 816,816 shares, compared to its average volume of 1,302,529. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $29,894.77, a price-to-earnings ratio of 49.08, a P/E/G ratio of 2.09 and a beta of 0.56. Edwards Lifesciences has a one year low of $92.35 and a one year high of $143.22.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. The company had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The business’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. equities analysts forecast that Edwards Lifesciences will post 4.53 EPS for the current year.
Edwards Lifesciences declared that its Board of Directors has initiated a stock repurchase plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.
In other news, VP Donald E. Bobo, Jr. sold 3,750 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $127.54, for a total transaction of $478,275.00. Following the transaction, the vice president now owns 19,608 shares of the company’s stock, valued at $2,500,804.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $114.08, for a total value of $604,624.00. The disclosure for this sale can be found here. Insiders have sold 142,903 shares of company stock worth $17,850,415 in the last ninety days. 2.13% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/03/20/edwards-lifesciences-ew-getting-somewhat-favorable-media-coverage-report-shows.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.